The earnings call presented a mixed outlook. While there are positive developments such as growth in the Surgical & Sports Medicine segment, proposed CMS payment reforms, and progress in the ReNu program, the company faced significant challenges with a decline in Advanced Wound Care revenue, overall revenue decrease, and reduced financial guidance.

Company Guidance

During the Second Quarter 2025 Earnings Conference Call, Organogenesis Holdings provided comprehensive guidance and insights into their performance and strategic developments. The company reported a net product revenue of $100.8 million for Q2, a 23% decrease year-over-year, influenced by a 25% decline in Advanced Wound Care products and a 16% increase in Surgical & Sports Medicine products. Gross profit was noted at $73.1 million, equating to 73% of net product revenue. The operating expenses were reduced by 21% to $113.6 million, resulting in an operating loss of $12.6 million. The GAAP net loss stood at $9.4 million, while the adjusted EBITDA loss was $3.6 million. Looking ahead, the company updated its 2025 revenue guidance to a range of $480 million to $510 million, with expected profitability influenced by a gross margin projection of 74% to 76%. Key strategic focuses included advocating for CMS policy reforms, expanding biomanufacturing capabilities, and advancing the ReNu program. The company also anticipated the reintroduction of Dermagraft by the second half of 2027 and emphasized the importance of new CMS payment proposals for the industry.

Surgical & Sports Medicine Revenue Growth

Net product revenue from Surgical & Sports Medicine products for the second quarter was $8.1 million, up 16%.

Proposed CMS Payment Reform

CMS announced a proposed Medicare physician fee schedule expected to bring long-term stabilization to the skin substitute markets and encourage innovation. This is seen as a transformational opportunity for Organogenesis.

ReNu BLA Submission Progress

ReNu program is on track for submission by the end of this year, with all patients completing the second Phase III study. Top line data results expected in September 2025.

Expanded Manufacturing Capacity

Expansion of biomanufacturing capabilities at the new facility in Smithfield, Rhode Island, to support the introduction of new products like Dermagraft and TransCyte.

Organogenesis Holdings (ORGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ORGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.06 / -	0.09	―	―	―
Aug 07, 2025	2025 (Q2)	-0.05 / -0.06	-0.13	51.54% (+0.07)	―
May 08, 2025	2025 (Q1)	-0.04 / -0.17	-0.015	-1033.33% (-0.16)	―
Feb 27, 2025	2024 (Q4)	-0.01 / 0.04	0.019	110.53% (+0.02)	―
Nov 12, 2024	2024 (Q3)	-0.02 / 0.09	0.036	150.00% (+0.05)	―
Aug 08, 2024	2024 (Q2)	<0.01 / -0.13	0.046	-382.61% (-0.18)	―
May 09, 2024	2024 (Q1)	-0.02 / -0.01	-0.003	-400.00% (-0.01)	―
Feb 29, 2024	2023 (Q4)	<0.01 / 0.02	0.071	-73.24% (-0.05)	―
Nov 09, 2023	2023 (Q3)	0.01 / 0.04	0.037	-2.70% (>-0.01)	―
Aug 09, 2023	2023 (Q2)	0.03 / 0.05	0.085	-45.88% (-0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ORGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$4.52	$4.56	+0.88%
May 08, 2025	$5.34	$3.06	-42.70%
Feb 27, 2025	$3.07	$6.21	+102.28%
Nov 12, 2024	$3.45	$4.43	+28.41%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Organogenesis Holdings Inc (ORGO) report earnings?

Organogenesis Holdings Inc (ORGO) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Organogenesis Holdings Inc (ORGO) earnings time?

Organogenesis Holdings Inc (ORGO) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ORGO EPS forecast?

ORGO EPS forecast for the fiscal quarter 2025 (Q3) is 0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing